{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"385.0","value":"18.4"}]}],"title":"Ang-(1-7) Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2840.0","value":"41.2"}]}],"title":"Ang-(1-7) Day 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.5","value":"21.3"}]}],"title":"Ang II Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.5","value":"31.5"}]}],"title":"Ang II Day 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"127","value":"22.5"}]}],"title":"Ang I Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"52.7","value":"17.5"}]}],"title":"Ang I Day 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"66.4","value":"65.6"}]}],"title":"VEGF Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.0","value":"49.6"}]}],"title":"VEGF Day 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.1","value":"4.3"}]}],"title":"PIGF Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.7","value":"3.0"}]}],"title":"PIGF Day 22"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Patients receive therapeutic angiotensin-(1-7) SC once daily in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Antiangiogenesis Therapy)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Baseline and Day 22","title":"Plasma Levels of Angiogenic Peptides Including Placental Growth Factor (PlGF)","type":"SECONDARY","unitOfMeasure":"pg/mL"}